 Humanigen Inc NASDAQ: HGEN announced that The Lancet Respiratory Medicine published results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalized COVID-19 patients. The Lancet paper concludes, LIVE-AIR showed that lenzilumab treatment of hospitalized patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo. 